Telix Pharmaceuticals completed enrollment in BiPASS, its prostate imaging study, and aligned with the FDA on a U.S. NDA pathway. If approved, the route could support reimbursement as a new product and broaden access to 68Ga-PSMA-PET imaging for a larger patient population.

Key Highlights

  • The announcement was issued on September 2, 2026, from Melbourne, Australia.
  • Telix Pharmaceuticals completed patient enrollment in its BiPASS study.
  • BiPASS evaluates Illuccix and Gozellix with MRI and PSMA-PET/CT before prostate biopsy.
  • Telix aligned with the FDA on a potential NDA pathway that could support reimbursement as a new product.

Telix Pharmaceuticals Ltd completed patient enrollment in its BiPASS study, which evaluates prostate cancer imaging before biopsy. The company also aligned with the U.S. Food and Drug Administration on a New Drug Application pathway that, if approved, could support reimbursement as a new product and widen patient access to 68Ga-PSMA-PET imaging.

BiPASS Study Reaches Enrollment Milestone

BiPASS is assessing Telix’s commercial PSMA-PET imaging agents, Illuccix and Gozellix, in the pre-biopsy setting. The study combines MRI with PSMA-PET/CT to evaluate diagnostic performance in detecting prostate cancer before tissue sampling. Telix describes the trial as prospective and open-label, with participation from the U.S. and Australia. The study is intended to determine whether this imaging combination can improve diagnostic accuracy, reduce unnecessary biopsies or help physicians target biopsies more effectively than current practice.

FDA Pathway Targets Reimbursement Access

The FDA alignment concerns a potential U.S. NDA route for BiPASS. Approval would support reimbursement as a new product, according to the announcement, rather than relying on an existing reimbursement pathway. BiPASS therefore links its diagnostic evaluation with a potential regulatory and reimbursement route for the imaging agents.